CGP-39551
Overview[edit]
CGP-39551 is a chemical compound that acts as a competitive antagonist of the NMDA receptor. It is primarily used in research settings to study the role of NMDA receptors in various physiological and pathological processes.
Chemical Structure[edit]

CGP-39551 is chemically known as (E)-(4-Amino-5-ethoxy-2-methyl-5-oxopent-2-en-1-yl)phosphonic acid. The structure of CGP-39551 includes a phosphonic acid group, which is crucial for its activity as an NMDA receptor antagonist.
Mechanism of Action[edit]
CGP-39551 functions by binding to the glutamate site on the NMDA receptor, thereby inhibiting the action of glutamate, which is the primary excitatory neurotransmitter in the central nervous system. This inhibition can help in reducing excitotoxicity, which is implicated in various neurological disorders.
Applications in Research[edit]
CGP-39551 is used extensively in neuroscience research to explore the role of NMDA receptors in synaptic plasticity, learning, and memory. It is also used to investigate the potential therapeutic effects of NMDA receptor antagonists in conditions such as epilepsy, ischemic stroke, and neurodegenerative diseases.
Pharmacological Properties[edit]
As a competitive antagonist, CGP-39551 competes with glutamate for binding to the NMDA receptor. This property makes it a valuable tool for dissecting the contributions of NMDA receptor-mediated signaling in various physiological and pathological contexts.
Safety and Toxicity[edit]
In research settings, the safety and toxicity of CGP-39551 are important considerations. While it is a potent antagonist, its effects are dose-dependent, and care must be taken to avoid potential neurotoxic effects associated with excessive NMDA receptor inhibition.
Related Pages[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian